Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT00171808
- Locations
- 🇩🇪
Ebersberg, Germany, Hamburg, Germany
🇩🇪Novartis Investigative Site, Tuebingen, Germany
🇩🇪Tuebingen, Germany, Heidelberg, Germany
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT00171847
- Locations
- 🇩🇪
Novartis Investigative Site, Tuebingen, Germany
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Duke University
- Target Recruit Count
- 33
- Registration Number
- NCT00134680
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Siteman Cancer Center, Washington University, St. Louis, Missouri, United States
🇺🇸Lombardi Cancer Institute, Georgetown University Medical Center, Washington, District of Columbia, United States
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
- Conditions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- University of Virginia
- Registration Number
- NCT00114270
- Locations
- 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 558
- Registration Number
- NCT00107263
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 842
- Registration Number
- NCT00097344
- Locations
- 🇺🇦
Research Site, Vinnitsa, Ukraine
🇷🇺Research site, Krasnodar, Russian Federation
Letrozole in Preventing Breast Cancer in Postmenopausal Women
- First Posted Date
- 2004-09-08
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 49
- Registration Number
- NCT00090857
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
- First Posted Date
- 2004-06-17
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 33
- Registration Number
- NCT00004251
Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 115
- Registration Number
- NCT00084396
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.